Delivery Order SPE2DB22D2211-SPE2DB25FSDWG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,679.97 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg, with an ultimate completion date of September 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $2,565.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $1,269.13 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $2,437.80 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on August 7, 2025, with completion scheduled for August 8, 2025. This non-competitive, firm fixed-price delivery order represents a single pharmaceutical transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $1,167.14 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg on August 27, 2025. This competitively awarded, firm fixed price contract represents a single delivery order with an ultimate completion date of August 28, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $2,943.88. This is a non-set-aside competitive award with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 7, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $2,205.48 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100-count units) on August 28, 2025, with completion scheduled for August 29, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and specifies performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,946.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on September 18, 2025, with completion scheduled for September 19, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $11,625.10 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This firm fixed-price contract represents a non-competitive set-aside delivery against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to the contractor's corporate office location in...
- The Defense Logistics Agency awarded a $1,547.46 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on August 19, 2025, with an ultimate completion date of August 20, 2025. This non-set-aside, firm fixed price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The order will be fulfilled from the vendor's corporate office location in...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDWGDelivery Order
The Defense Logistics Agency awarded a $2,846.53 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg on August 28, 2025, with completion scheduled for August 29, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company's IDC vehicle enables the supply of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including medications across multiple therapeutic domains. This delivery order for Vyvanse, a controlled substance commonly prescribed for attention deficit hyperactivity disorder, exemplifies the routine pharmaceutical distribution activities executed under the broader prime vendor contract to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 8/28/25 |